Is There a Difference Between Oxycodone and Hydrocodone?

Oxycodone and hydrocodone are both semi-synthetic opioids derived from compounds found in the opium poppy, and they work through the same basic mechanism in the brain. For most people taking a standard dose for acute pain, the two drugs feel similar and provide comparable relief. But the differences between them, while subtle, are real and sometimes clinically meaningful: oxycodone is roughly one and a half times more potent milligram for milligram, it carries a somewhat higher abuse potential, and the two drugs have followed very different regulatory paths in the United States.

How They Work in the Body

Both oxycodone and hydrocodone relieve pain primarily by binding to mu-opioid receptors in the brain and spinal cord. In lab assays that measure how tightly various opioids latch onto this receptor, oxycodone and hydrocodone fall into the same intermediate-binding category, alongside morphine and methadone.¹ That shared receptor profile is why the two drugs produce such similar effects: pain relief, sedation, euphoria, constipation, and respiratory depression all trace back to mu-receptor activation.

Where the drugs diverge is in how the body processes them. Both are metabolized by cytochrome P450 enzymes in the liver, but the details differ. There has been long-standing debate over whether hydrocodone is partly a “prodrug,” meaning it needs to be converted by the CYP2D6 enzyme into an active metabolite (hydromorphone) before it fully works. Oxycodone, by contrast, is clearly active on its own and does not depend on CYP2D6 activation to produce pain relief, though that enzyme does convert some of it into the more potent oxymorphone.² In practice, both drugs also pass through the CYP3A4 pathway, which means other medications that speed up or slow down these liver enzymes can change how much active drug ends up in your bloodstream.

Once swallowed, the two drugs behave almost identically in terms of timing. Both reach peak blood levels within one to two hours, and both have a half-life in the range of about three to five hours for immediate-release tablets.³ Oxycodone has a high oral bioavailability, typically reported between 60 and 87 percent, which is one reason it works well as a pill.³ Hydrocodone’s bioavailability is in a similar range, and both drugs reach similar peak concentrations on comparable timelines.⁴

The Potency Gap

If you compare the two drugs milligram for milligram, oxycodone is the stronger one. A controlled study in volunteers who were not regular drug users found that oxycodone combined with acetaminophen was approximately 1.5 times more potent than the same milligram dose of hydrocodone with acetaminophen.⁵ A separate study using intravenous dosing in recreational opioid users confirmed the same rank order: oxycodone was more potent than morphine, which in turn was more potent than hydrocodone.⁶

This potency difference matters when doctors convert patients from one opioid to another, but it does not mean oxycodone is “better” for pain. In standard prescribing, the dose is simply adjusted. A 5 mg oxycodone tablet and a 7.5 mg hydrocodone tablet land roughly in the same analgesic ballpark. The potency gap matters more in clinical pharmacology than in your lived experience at normal prescribed doses.

Do They Actually Relieve Pain Differently?

For most types of acute pain, the answer is no. A double-blind randomized trial comparing the two drugs in emergency department patients with fractures found no difference in pain scores at either 30 minutes or 60 minutes after dosing.⁷ When the dose is adjusted properly, both drugs do the same job for the same kinds of pain.

A more recent and much larger study, however, found a modest difference in a specific surgical setting. Among patients undergoing hip or knee replacement, those given hydrocodone had slightly lower composite pain scores and used significantly less total opioid (measured in morphine milligram equivalents) than those given oxycodone.⁸ The pain score difference was statistically significant but small in absolute terms. Mobility, anxiety, and depression scores after surgery did not differ between the two groups.⁸ Whether this finding reflects a genuine advantage for hydrocodone in joint surgery or is an artifact of dosing practices remains an open question.

Side Effects and Subjective Experience

At low doses, both drugs produce few noticeable side effects beyond mild sedation and the typical opioid constellation of constipation and nausea. But as the dose climbs, the profiles start to separate. In a controlled comparison, the 10 mg oxycodone-acetaminophen combination produced a broader range of subjective effects than the same dose of hydrocodone-acetaminophen. Both impaired psychomotor performance at the higher dose, but oxycodone tended to generate more measurable drug “liking” and mood effects.⁹

This broader subjective profile at higher doses is part of what makes oxycodone potentially more reinforcing, a concept closely tied to abuse liability. In a study of people who already had a history of prescription opioid misuse, oxycodone, hydrocodone, and hydromorphone all produced dose-dependent increases in “high” and “liking” ratings compared to placebo. All three opioids were clearly reinforcing, but the pattern of effects was qualitatively similar across drugs.¹⁰ The intravenous potency study mentioned earlier also found that oxycodone produced “liking” effects at lower doses, consistent with its higher potency.⁶

The Acetaminophen Problem

For years, hydrocodone was available in the United States almost exclusively in combination products paired with acetaminophen (Vicodin, Norco) or ibuprofen. Oxycodone was available both in combination form (Percocet) and as a standalone drug (OxyContin, Roxicodone). This distinction mattered enormously for safety, because acetaminophen has a surprisingly narrow margin between a therapeutic dose and a toxic one.¹¹

The danger is not the opioid itself but the acetaminophen hitchhiker. If you take more hydrocodone pills to chase better pain control, you may inadvertently push your acetaminophen intake into liver-toxic territory. A large retrospective study of over five million opioid-acetaminophen prescriptions found that about 8 percent exceeded the recommended maximum daily dose of acetaminophen, and the products most often involved were those containing hydrocodone. Nearly a quarter of patients who were later diagnosed with liver dysfunction had received an opioid-acetaminophen prescription in the preceding 90 days.¹² Separately, research has shown that up to half of acetaminophen overdoses are unintentional, with opioid-acetaminophen combinations a leading contributor, and liver injury occurs in about 17 percent of adults with such unintentional overdoses.¹³

The FDA eventually responded by limiting the amount of acetaminophen in combination products to 325 mg per tablet. And in 2014, a single-entity extended-release hydrocodone product (Zohydro ER, later Hysingla ER) reached the market, giving prescribers a hydrocodone option without any acetaminophen for the first time.¹⁴ If you are taking either drug, knowing whether your formulation contains acetaminophen and tracking your total daily intake from all sources, including over-the-counter cold medicines, is genuinely important for your liver.

Scheduling and Regulation in the United States

Until October 2014, hydrocodone combination products were classified as Schedule III controlled substances, while oxycodone in all forms was Schedule II. The practical difference was enormous: Schedule III drugs could be called in by phone, refilled up to five times, and prescribed with a 90-day supply. Schedule II drugs required a new written prescription each time. Hydrocodone’s lower scheduling made it dramatically easier to prescribe, and it became the most prescribed opioid in the country by a wide margin.

When the DEA reclassified hydrocodone combination products to Schedule II in October 2014, prescribing dropped immediately. One national analysis estimated a sudden decrease of about 4.6 million hydrocodone prescriptions right after rescheduling, with continued declines in the months that followed.¹⁵ In Ohio alone, the rescheduling was associated with an immediate drop of over 26,000 prescriptions and an ongoing monthly decline on top of a preexisting downward trend.¹⁶

The unintended consequence was substitution. Studies consistently found that after hydrocodone was rescheduled, prescribing of codeine products jumped substantially, along with increases in oxycodone and tramadol.¹⁷ One analysis found a level increase of about 1.1 million oxycodone prescriptions immediately after the hydrocodone rescheduling date.¹⁵ In other words, some of the reduction in hydrocodone use was simply shifted onto other opioids rather than resulting in less opioid use overall.

Genetics and Why the Same Pill Hits People Differently

Your liver’s CYP2D6 enzyme is responsible for converting both hydrocodone and oxycodone into their more potent metabolites. People inherit different versions of the gene that codes for this enzyme, and roughly 5 to 10 percent of people of European descent are “poor metabolizers” who produce little or no functional CYP2D6. On the other end, a smaller percentage are “ultra-rapid metabolizers” who convert these drugs faster than average.

In theory, this should mean that poor metabolizers get less pain relief from both drugs. A case report described an 85-year-old woman identified as a CYP2D6 poor metabolizer who could not tolerate codeine, had a bad experience with oxycodone combined with tramadol, but appeared to respond better to hydrocodone after her doctor was informed of her genetic status.¹⁸ However, a larger study looking specifically at post-surgical patients found that CYP2D6 metabolizer status did not meaningfully predict how much hydrocodone or oxycodone people consumed after surgery, or how well their pain was controlled.¹⁹

The disconnect between what genetics should predict and what actually happens in practice likely reflects the fact that both drugs have multiple metabolic pathways. Unlike codeine, which depends heavily on CYP2D6 to become morphine, oxycodone and hydrocodone can still provide analgesia through their parent compounds and through metabolites produced by other enzymes. Pharmacogenomic testing is increasingly available, but for these two opioids specifically, the clinical guidance based on CYP2D6 status remains less clear-cut than it is for codeine.

Risks in Older Adults

Older adults metabolize drugs more slowly and are more vulnerable to opioid side effects like falls, confusion, and respiratory depression. A large comparative safety study matched over 6,000 older adults in each of five opioid groups and tracked outcomes after starting therapy. At 30 days, oxycodone users had significantly higher all-cause mortality compared with hydrocodone users. Codeine also showed elevated mortality risk. Fracture risk, a major concern in older adults prone to falls, was similar between hydrocodone and oxycodone but substantially lower for tramadol. Gastrointestinal side effects did not differ across the opioid groups.²⁰

That mortality finding is striking and worth contextualizing. Observational studies like this one cannot prove that oxycodone itself caused the higher death rate; it may reflect differences in the patients who were prescribed each drug, the doses used, or unmeasured health factors. Still, the finding has been influential in geriatric prescribing, where hydrocodone is sometimes preferred as a starting opioid because of its somewhat more reassuring safety profile in this particular population.

Prescribing Volume and Cost

Hydrocodone has historically been the more widely prescribed of the two by a large margin. An analysis of US Medicaid programs from 1991 through 2019 found that hydrocodone accounted for about 247 million prescriptions over that period, compared with roughly 112 million for oxycodone. Despite being prescribed less often, oxycodone cost Medicaid programs more: about $7.3 billion in total spending on oxycodone versus about $3.3 billion on hydrocodone.²¹ The spending gap reflects both the higher per-unit cost of oxycodone products (especially extended-release formulations like OxyContin) and the broader range of available dosage forms. Hydrocodone combination tablets, by contrast, have been available as cheap generics for decades.

The rescheduling of hydrocodone in 2014 narrowed the prescribing gap somewhat, but hydrocodone remains one of the most commonly dispensed medications in the country. For many physicians, especially in primary care and dentistry, hydrocodone combination products are still the default short-course opioid for moderate pain, partly out of familiarity and partly because of perceived lower abuse risk at standard doses.

Overdose and Respiratory Depression

All opioids can suppress breathing at high enough doses, and this is the mechanism by which opioid overdoses kill. In a study examining risk factors for severe respiratory depression in opioid overdose cases, the most frequently involved drugs were oxycodone and methadone. The percentage of overdose cases that resulted in severe respiratory depression varied by drug, with fentanyl at the top and codeine at the bottom.²² Oxycodone’s higher potency means a smaller number of tablets can push a person into dangerous territory, particularly if combined with alcohol, benzodiazepines, or other sedating drugs. But in the current overdose crisis, illicitly manufactured fentanyl has dwarfed the contribution of both prescription oxycodone and hydrocodone to overdose deaths. The risk profile of these two drugs is best understood in the context of prescribed, known-dose use rather than the illicit supply.

When Your Doctor Picks One Over the Other

In practice, the choice between oxycodone and hydrocodone often comes down to the clinical setting, the prescriber’s experience, and the available formulations rather than a dramatic pharmacological advantage of one over the other. Emergency departments and surgeons sometimes lean toward oxycodone for more severe pain because its higher potency allows smaller pill counts. Primary care doctors and dentists have historically favored hydrocodone combinations for short-term moderate pain. Chronic pain management may involve extended-release formulations of either drug, though the options differ: extended-release oxycodone (OxyContin) has been available for decades, while extended-release hydrocodone only arrived in 2013.

For patients with liver disease or those already taking acetaminophen for other reasons, a standalone opioid product without acetaminophen is preferable, which has traditionally pointed toward oxycodone formulations. Now that single-entity hydrocodone exists, that consideration matters less than it used to. For older adults, the comparative safety data give some edge to hydrocodone as a starting choice. For anyone with a history of substance use disorder, the slightly higher reinforcing profile of oxycodone is worth weighing, though both drugs carry real abuse liability and neither should be considered “safe” in that regard. Ultimately, the two drugs are far more alike than different, and the decision between them is usually one of practical clinical judgment rather than a stark either-or based on pharmacology alone.

1
PubMed. Uniform assessment and ranking of opioid μ receptor binding constants for selected opioid drugs
2
PubMed Central. Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, Part II
3
PubMed. Oxycodone: a pharmacological and clinical review
4
PubMed. Minor and Short-Acting Opioids
5
PubMed. Within-subject comparison of the psychopharmacological profiles of oral hydrocodone and oxycodone combination products in non-drug-abusing volunteers
6
PubMed Central. Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies
7
PubMed. Comparison of oxycodone and hydrocodone for the treatment of acute pain associated with fractures: a double-blind, randomized, controlled trial
8
JAMA Network Open. Hydrocodone vs Oxycodone and Postoperative Pain and Opioid Use in Joint Arthroplasty
9
PubMed. Subjective, psychomotor, and physiological effects profile of hydrocodone/acetaminophen and oxycodone/acetaminophen combination products
10
PubMed Central. The Relative Abuse Liability of Oral Oxycodone, Hydrocodone and Hydromorphone Assessed in Prescription Opioid Abusers
11
The Journal of the American Dental Association. The Therapeutic Applications of and Risks Associated With Acetaminophen Use: A Review and Update
12
PubMed. Opioid-paracetamol prescription patterns and liver dysfunction: a retrospective cohort study in a population served by a US health benefits organization
13
PubMed. A perspective on the epidemiology of acetaminophen exposure and toxicity in the United States
14
PubMed Central. Effectiveness and Safety of Once-Daily Extended-Release Hydrocodone in Individuals Previously Receiving Immediate-Release Oxycodone for Chronic Pain
15
PubMed Central. The Impact of Hydrocodone Rescheduling on Utilization, Abuse, Misuse, and Overdose Deaths
16
Pain Medicine. Effects of Rescheduling Hydrocodone on Opioid Prescribing in Ohio
17
American Journal of Health-System Pharmacy. Evaluation of opioid prescribing after rescheduling of hydrocodone-containing products
18
PubMed. Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer
19
Frontiers in Pharmacology. CYP2D6 phenotype and post-surgical pain control with hydrocodone and oxycodone
20
Archives of Internal Medicine. The Comparative Safety of Opioids for Nonmalignant Pain in Older Adults
21
PubMed Central. Utilization, Spending, and Price of Opioid Medications in the US Medicaid Programs Between 1991 and 2019
22
PubMed Central. Risk factors for severe respiratory depression from prescription opioid overdose